加科思：JAB-21822與JAB-3312聯合用藥可協同抑制腫瘤生長| on.cc 東網| LINE TODAY
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
:%0A%0AJAB-3312%20for%20Solid%20Tumors,%20Adult.png?md=1 "JAB-3312 for Solid Tumors, Adult Clinical Trial 2023 | Power")
JAB-3312 for Solid Tumors, Adult Clinical Trial 2023 | Power
直冲最前沿，本土药械企业与跨国公司“优势互补”
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy | Journal of Medicinal Chemistry
Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022
KRAS抑制剂战火纷飞，大小公司各显神通
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
Small‐Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview - Mitra - 2021 - ChemMedChem - Wiley Online Library
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond - Cancer Treatment Reviews
医药魔方
临床招募| JAB-3312免疫+靶向双重作用治疗晚期实体瘤- 知乎
JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加科思藥業集團有限公司截至2020年12月31日止年度的年度業績公告
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
Strategies to overcome drug resistance using SHP2 inhibitors - ScienceDirect
美银证券盘点全球SHP2研发现状，称加科思为全球黑马| 会员动态_生物_医药_写意
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes | npj Precision Oncology
安进带火的KRAS 抑制剂JAB-3312 在中国的临床申请获得承办
企业快讯| 新药临床试验、重点实验室揭牌成立……北京经开区医疗企业喜讯连连！_澎湃号·政务_澎湃新闻-The Paper
Small‐Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview - Mitra - 2021 - ChemMedChem - Wiley Online Library
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies - ScienceDirect
Jab Auto Service (@JABAutoService) / Twitter
